The role of HbA1c in the diagnosis of diabetes mellitus in Australia

Medical Journal of Australia

Volumn 197, Issue 4, 2012, Pages 220-221

  d'Emden, Michael C ^a,b   Shaw, Jonathan E ^c   Colman, Peter G ^d   Colagiuri, Stephen ^e   Twigg, Stephen M ^e   Jones, Graham R D ^f,g   Goodall, Ian ^h,i   Schneider, Hans G ^j   Wah Cheung, N ^k  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b Australian Diabetes Society   (Australia)

^c BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^d ROYAL MELBOURNE HOSPITAL   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f ST VINCENT S HOSPITAL   (Australia)

^g Quality Assurance Programs   (Australia)

^h Royal College of Pathologists of Australasia ^*

ⁱ Australasian Association of Clinical Geneticists   (Australia)

^j ALFRED HEALTH   (Australia)

^k WESTMEAD HOSPITAL   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; BIOLOGICAL MARKER; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ARTICLE; AUSTRALIA; CARDIOVASCULAR RISK; COST BENEFIT ANALYSIS; DETERIORATION; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE MARKER; EARLY DIAGNOSIS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; ORAL GLUCOSE TOLERANCE TEST; PATIENT ATTITUDE; PATIENT MONITORING; PRACTICE GUIDELINE; RISK REDUCTION; BLOOD; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS;

AUSTRALIA; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS;

EID: 84874357156     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/mja12.10988     Document Type: Article

References (20)

1. Dunstan DW, Zimmet PZ, Welborn TA, et al. The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care 2002; 25: 829-834.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
3. Holman RR, Paul SK, Bethel MA, et al. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
4. Colman PG, Thomas DW, Zimmet PZ, et al. New classification and criteria for diagnosis of diabetes mellitus. Position statement from the Australian Diabetes Society, New Zealand Society for the Study of Diabetes, Royal College of Pathologists of Australasia and Australasian Association of Clinical Biochemists. Med J Aust 1999; 170: 375-378.
5. World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation. Geneva: WHO, 2006.
6. Balkau B, Bertrais S, Ducimetiere P, Eschwege E. Is there a glycemic threshold for mortality risk. Diabetes Care 1999; 22: 696-699.
7. Kirkman MS, Kendall DM. Hemoglobin A1c to diagnose diabetes: why the controversy over adding a new tool? Clin Chem 2011; 57: 255-257.
8. Sacks DB. A1c versus glucose testing: a comparison. Diabetes Care 2011; 34: 518-523.
9. Valentine NA, Alhawassi TM, Roberts GW, et al. Detecting undiagnosed diabetes using glycated haemoglobin: an automated screening test in hospitalised patients. Med J Aust 2011; 194: 160-164.
10. Colagiuri S, Lee CM, Wong TY, et al. Glycemic thresholds for diabetes-specific retinopathy: implications for diagnostic criteria for diabetes. Diabetes Care 2011; 34: 145-150.
11. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412.
12. Khaw KT, Wareham N, Bingham S, et al. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 2004; 141: 413-420.
13. Selvin E, Steffes MW, Zhu H, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010; 362: 800-811.
14. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus. Report of a World Health Organization Consultation. Diabetes Res Clin Pract 2011; 93: 299-309.
15. American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care 2011; 34 Suppl 1: S11-S61.
16. Colagiuri S, Davies D, Girgis S, Colagiuri R. National evidence based guideline for case detection and diagnosis of type 2 diabetes. Canberra: Diabetes Australia and National Health and Medical Research Council, 2009.
17. Guyatt GH, Oxman AD, Vist GE, et al; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924-926.
18. Little RR, Rohlfing CL, Sacks DB; National Glycohemoglobin Standardization Program (NGSP) Steering Committee. Status of hemoglobin A1c measurement and goals for improvement: from chaos to order for improving diabetes care. Clin Chem 2011; 57: 205-214.
19. RCPA Chemical Pathology Programs. Program information circular: glycohaemoglobin program, whole blood samples, 22/06/09. http://www.rcpaqap.com.au/chempath/documents/uploadedfiles/455_Whole%20Blood%20Samples%20270809.pdf (accessed Jun 2012).
20. Gallagher EJ, Le Roith D, Bloomgarden ZT. Review of hemoglobin A1c in the management of diabetes. J Diabetes 2009; 1: 9-17.